Jpmorgan Chase & CO T Scan Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 31,805 shares of TCRX stock, worth $97,959. This represents 0.0% of its overall portfolio holdings.
Number of Shares
31,805
Previous 16,364
94.36%
Holding current value
$97,959
Previous $95,000
66.32%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding TCRX
# of Institutions
89Shares Held
41.8MCall Options Held
0Put Options Held
0-
Lynx1 Capital Management LP San Juan, PR5.22MShares$16.1 Million9.31% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA5MShares$15.4 Million1.08% of portfolio
-
Black Rock Inc. New York, NY4.46MShares$13.7 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA4.4MShares$13.6 Million0.04% of portfolio
-
Bvf Inc San Francisco, CA2.99MShares$9.21 Million0.47% of portfolio
About TScan Therapeutics, Inc.
- Ticker TCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,929,800
- Market Cap $58.3M
- Description
- TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...